EU reviews for Sanofi’s Dupixent, cemiplimab

3rd April 2018 Uncategorised 0

European regulators have agreed to review Sanofi and Regeneron’s Dupixent for asthma and cemiplimab for advanced cutaneous squamous cell carcinoma.

More: EU reviews for Sanofi’s Dupixent, cemiplimab
Source: News